187 related articles for article (PubMed ID: 19716543)
1. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
[TBL] [Abstract][Full Text] [Related]
2. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
3. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
4. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
5. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
Ward A; Greenberg V; Valcarcel B; Boelig RC; Al-Kouatly HB; Berghella V
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
[TBL] [Abstract][Full Text] [Related]
7. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
8. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
9. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
11. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
13. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
15. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
16. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
17. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
18. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
19. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
20. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
